Clinical Trials Directory

Trials / Completed

CompletedNCT04500912

Comparison of the Supraflex Cruz 60 Micron Versus the Ultimaster Tansei 80 Micron in HBR PCI Population

Comparison of the Supraflex Cruz 60 Micron Stent Strut Versus the Ultimaster Tansei 80 Micron Stent Strut in High Bleeding Risk PCI Population

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
736 (actual)
Sponsor
Pieter C.Smits · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study compares the outcome of the ultrathin stent strut Supraflex Cruz stent to the thin stent strut Ultimaster Tansei stent in a PCI population at high risk for bleeding (HBR).

Detailed description

Study design: An Investigator-initiated, multi-center, randomized clinical trial in HBR patients receiving PCI with Supraflex Cruz or Ultimaster Tansei stents Study population: 2 x 368 (736) patients, who undergo a PCI and are at high risk for bleeding (HBR). Intervention: Patients are treated according to the randomized regimen at index PCI and at planned staged procedures. Either with the ultrathin stent strut Supraflex Cruz stent to the thin stent strut Ultimaster Tansei stent DAPT treatment (combination and duration) is according to the Guidelines of the European Society of Cardiology for Myocardial Revascularization. Follow-up is scheduled at 1 month, 6 months and 12 months post index PCI procedure. Primary study parameters/outcome of the study: The primary endpoint Net Adverse Clinical Endpoints (NACE) defined as a composite of cardiovascular death, myocardial infarction, target vessel revascularization, stroke and bleeding events defined as BARC 3 or 5 at 12 months follow-up after the index PCI.

Conditions

Interventions

TypeNameDescription
DEVICESupraflex Cruz 60 Micronpercutaneous coronary intervention
DEVICEUltimaster Tansei 80 Micronpercutaneous coronary intervention

Timeline

Start date
2020-09-14
Primary completion
2023-09-01
Completion
2023-09-01
First posted
2020-08-05
Last updated
2023-09-15

Locations

11 sites across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT04500912. Inclusion in this directory is not an endorsement.